<DOC>
	<DOCNO>NCT02111070</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity IL-YANG Inactivated Split Influenza Vaccine ( IL-YANG FLU Vaccine Vial INJ . ) administer single intramuscular injection</brief_summary>
	<brief_title>Immunogenicity Safety Study Inactivated Split Influenza Vaccine ' Healthy Korean Male Subjects</brief_title>
	<detailed_description>This open-label study . Subjects provide voluntary write informed consent underwent protocol-specific assessment test within 4 week prior administration study vaccine , meet inclusion/exclusion criterion consider eligible sequentially enrol study . Subjects enrol study receive 0.5ml study vaccine intramuscular injection deltoid muscle , return clinic every day first 3 day . On Day 14 post-vaccination , subject underwent safety assessment . On Day 28 post-vaccination , subject return safety immunogenicity assessment .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male 20 55 year age screen Body weight ≥ 55kg within ±20 % ideal body weight ( ideal body weight = ( height cm 100 ) X 0.9 ) screening Subjects congenital chronic disease consider suitable study screen assessment ( investigator 's opinion , medical history , physical examination , laboratory test , chest Xray , ECG ) conduct within 28 day prior vaccination Subjects give , fully understood , information study , make voluntary decision , provide write informed consent , participate study comply applicable study requirement Subjects prevaccination HI antibody titer ≥ 1:40 Subjects know suspected infection HAV , HBV , HCV , HIV VDRL ( via ELISA screen medical history take ) Subjects concurrent past history immune deficiency disease Subject participate blood donation within 1 week prior vaccination , plan participate blood donation Day 1 Month 7 postvaccination Subject history GuillainBarre syndrome Subject hemophilia , thrombocytopenia treat anticoagulant , increased risk serious bleed intramuscular injection Subjects concurrent past history , malignant tumor internal organ blood vessel skin metastasis Subjects know allergy drug , food latex , history anaphylaxis Subjects acute fever body temperature &gt; 38.0 Cº within 72 hour prior administration study vaccine symptom suspect acute disease within 14 day prior administration study vaccine Subjects receive another experimental drug vaccine within 28 day administration study vaccine plan receive another experimental drug vaccine study . Subjects previously receive immunoglobulin bloodderived product within last 3 month prior administration study vaccine , expect treat immunoglobulin bloodderived product study Subjects receive , schedule receive , systemic immunosuppressive therapy , radiation therapy highdose steroid therapy within last 6 month prior administration study Subjects receive , expect receive , medication list : Within 28 day prior administration study vaccine : Oriental herbal medicine , Within 14 day prior administration study vaccine : Prescription drug , Within 7 day prior administration study vaccine : Overthecounter medicine ( include vitamin/mineral supplement ) Subjects history , suspect , drug abuse ( amphetamine , barbiturate , opioids , benzodiazepine , etc . ) base subject interview physical examination . Subjects excessive consumption caffeine ( &gt; 5 cups/day ) alcohol ( &gt; 3 units/day , 1unit= 10g 12.5ml pure alcohol ) , excessive smoking ( &gt; 10 cigarettes/day ) Subject know allergy egg , chicken , component study vaccine Subjects investigator 's opinion , may suitable vaccination may interfere objective assessment study outcome .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Influenza vaccine</keyword>
	<keyword>Split influenza vaccine</keyword>
</DOC>